171 related articles for article (PubMed ID: 34275123)
1. Secukinumab Demonstrated High Effectiveness in Vietnamese Patients with Moderate-To-Severe Plaque Psoriasis in a Real-World Clinical Setting: 16 Week Results from an Observational Study.
Nguyen HT; Pham NTU; Tran TNA; Nguyen NTT; Vu TTP
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1613-1621. PubMed ID: 34275123
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study.
Nguyen HT; Pham NTU; Tran TNA; Pham NN; Bui YT; Vu TTP
Dermatol Ther (Heidelb); 2023 Feb; 13(2):465-476. PubMed ID: 36472791
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes of secukinumab in adult patients with moderate-to-severe plaque psoriasis in China: A real-world multicenter retrospective study.
Ding Y; Li W; Guan X; Liu N; Zhou Y; Li G; Wang X; Wang Z; Xiao X; Yang B; Lv C; Zhang C; Shi Y
Clin Transl Sci; 2023 Oct; 16(10):1803-1814. PubMed ID: 37644777
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of secukinumab in patients with psoriasis and psoriatic arthritis in a Saudi real-world setting.
Al-Homood IA; Alajlan M; Alberdisi M; Alturki M; Ahmed AA; Zakaria N
Adv Rheumatol; 2024 Apr; 64(1):34. PubMed ID: 38685124
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Crowley JJ; Langley RG; Gordon KB; Pinter A; Ferris LK; Rubant S; Photowala H; Xue Z; Wu T; Zhan T; Beeck S; Shah M; Warren RB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):561-575. PubMed ID: 35050485
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U; Sfikakis PP; Gaffney K; Sator PG; von Kiedrowski R; Bounas A; Gullick N; Conrad C; Rigopoulos D; Lespessailles E; Romanelli M; Ghislain PD; Brandt-Jürgens J; Rashkov R; Aassi M; Orsenigo R; Perella C; Pournara E; Gathmann S; Jagiello P; Veit J; Augustin M
Adv Ther; 2020 Jun; 37(6):2865-2883. PubMed ID: 32378070
[TBL] [Abstract][Full Text] [Related]
7. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of secukinumab in patients with moderate-to-severe plaque psoriasis - a real life retrospective study.
Galica K; Lesiak A; Ciążyńska M; Noweta M; Bednarski I; Narbutt J
Postepy Dermatol Alergol; 2021 Dec; 38(6):973-978. PubMed ID: 35126003
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
[No Abstract] [Full Text] [Related]
10. Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study.
Körber A; Thaçi D; von Kiedrowski R; Bachhuber T; Melzer N; Kasparek T; Kraehn-Senftleben G; Amon U; Augustin M
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):411-419. PubMed ID: 28960469
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy.
Dastoli S; Passante M; Loconsole F; Mortato E; Balato A; Piccolo V; Guarneri C; Macca L; Provenzano E; Valenti G; D'Amico D; Micali G; Musumeci ML; Palazzo G; Foti C; Romita P; Fabbrocini G; Megna M; Sammarra I; Bennardo L; Patruno C
J Dermatolog Treat; 2023 Dec; 34(1):2200868. PubMed ID: 37026590
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of secukinumab in moderate to severe psoriasis patients in Thailand: Characteristics, effectiveness, and safety.
Asawanonda P; Pattamadilok B; Chularojanamontri L; Chuamanochan M; Choonhakarn C; Chakkavittumrong P; Sangob N; Rajatanavin N
Dermatol Ther; 2022 Dec; 35(12):e15958. PubMed ID: 36279306
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between Change in Psoriasis Area and Severity Index and Dermatology Life Quality Index in Patients with Psoriasis: Pooled Analysis from Four Phase 3 Clinical Trials of Secukinumab.
Houghton K; Patil D; Gomez B; Feldman SR
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1373-1384. PubMed ID: 34110605
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study.
Megna M; Di Costanzo L; Argenziano G; Balato A; Colasanti P; Cusano F; Galluccio AG; Gambardella A; Lembo S; Mozzillo R; Scotto Di Luzio G; Fabbrocini G; Balato N
Expert Opin Biol Ther; 2019 Aug; 19(8):855-861. PubMed ID: 31140882
[No Abstract] [Full Text] [Related]
15. A Real-Life 208 Week Single-Centred, Register-Based Retrospective Study Assessing Secukinumab Survival and Long-Term Efficacy and Safety Among Greek Patients with Moderate to Severe Plaque Psoriasis, Including Difficult-to-Treat Manifestations Such as Genitals and Scalp.
Kyrmanidou E; Kemanetzi C; Stavros C; Trakatelli MG; Patsatsi A; Madia X; Ignatiadi D; Kalloniati E; Apalla Z; Lazaridou E
Dermatol Pract Concept; 2024 Apr; 14(2):. PubMed ID: 38810083
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study).
Foley P; Manuelpillai N; Dolianitis C; Cains GD; Mate E; Tronnberg R; Baker C
Australas J Dermatol; 2022 Aug; 63(3):303-311. PubMed ID: 35809080
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C; Riedl E; Maul JT; Torres T; Pinter A; Fabbrocini G; Daniele F; Brnabic A; Reed C; Wilhelm S; Holzkämper T; Schuster C; Puig L
Adv Ther; 2023 Mar; 40(3):869-886. PubMed ID: 36515803
[TBL] [Abstract][Full Text] [Related]
18. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study.
Augustin M; Sator PG; von Kiedrowski R; Conrad C; Rigopoulos D; Romanelli M; Ghislain PD; Torres T; Ioannides D; Aassi M; Schulz B; Jagiello P;
J Eur Acad Dermatol Venereol; 2022 Oct; 36(10):1796-1804. PubMed ID: 35696305
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study.
Foley P; Spelman L; Murrell DF; Mate E; Tronnberg R; Lowe PM
Australas J Dermatol; 2022 Aug; 63(3):312-320. PubMed ID: 35816576
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.
Notario J; Deza G; Vilarrasa E; Valentí F; Muñoz C; Mollet J; Rocamora V; Carrascosa JM; Del Alcázar E; Alsina M; Vidal D; Puig L; López-Ferrer A; Riera J; Gallardo F; Ferran M
J Dermatolog Treat; 2019 Aug; 30(5):424-429. PubMed ID: 30244618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
